CAJ | 학술논문

探讨DPP－4抑制剂对新诊断Ⅱ型糖尿病患者的有效性及安全性．120例新诊断Ⅱ型糖尿病患者被随机分为观察组和对照组，对照组给予二甲双胍常规治疗，观察组给予二甲双胍＋二肽基肽酶－4（DPP－4）抑制剂，随访12周，观察两组空腹血糖（FPG）、餐后两小时血糖（2hPG）、HbA1c、BMI及低血糖发生情况．12周治疗后观察组2hPG和HbA1c相较于对照组显著下降（P＜0．05），观察组HbA1c达标率为82％，显著高于对照组的67％（P＜0．05），两组治疗后BMI及低血糖发生率无显著差异（P＞0．05）．DPP－4抑制剂与二甲双胍联合应用治疗新诊断Ⅱ型糖尿病效果更好．
탐토DPP－4억제제대신진단Ⅱ형당뇨병환자적유효성급안전성．120례신진단Ⅱ형당뇨병환자피수궤분위관찰조화대조조，대조조급여이갑쌍고상규치료，관찰조급여이갑쌍고＋이태기태매－4（DPP－4）억제제，수방12주，관찰량조공복혈당（FPG）、찬후량소시혈당（2hPG）、HbA1c、BMI급저혈당발생정황．12주치료후관찰조2hPG화HbA1c상교우대조조현저하강（P＜0．05），관찰조HbA1c체표솔위82％，현저고우대조조적67％（P＜0．05），량조치료후BMI급저혈당발생솔무현저차이（P＞0．05）．DPP－4억제제여이갑쌍고연합응용치료신진단Ⅱ형당뇨병효과경호．
In this paper, the therapeutic effect and reliability of Dpp-4 inhibitors on therapy in the newly diagnosed T2DM patients was investigated.120 newly diagnosed T2DM patients were randomized into observation group and control group.The control group was given met-formin, while the observation group was given Dpp -4 inhibitors and metformin for 12 weeks. The fasting plasma glucose ( FPG ) , two -hour postprandial plasma glucose (2hPG), hemoglobin A1c(HbA1c), body mass index(BMI)and the incidence of hypogly-cemia in both groups were observed.After 12 -weeks treatment, the levels of 2hPG and HbA1c decreased significantly in observation group compared with the control group( P<0. 05).The targeting rate of HbA1c in the observation group was 82% that was significantly higher than that of control group (P<0.05).The changes in BMI and the incidence of hy-poglycemia of two groups were not significantly different ( P >0.05 ) .The combination of Dpp-4 inhibitors with metformin was more effective for the treatment of newly diagnosed T2DM.